Related references
Note: Only part of the references are listed.Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer
E. Hessmann et al.
GUT (2018)
The role of stromal cancer-associated fibroblasts in pancreatic cancer
Dagny von Ahrens et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters
Patricia Dauer et al.
PANCREATOLOGY (2017)
Chemoresistance in pancreatic cancer: Emerging concepts
Manu Gnanamony et al.
ONCOLOGY LETTERS (2017)
Development of a Gemcitabine-Polymer Conjugate with Prolonged Cytotoxicity against a Pancreatic Cancer Cell Line
Fanny Joubert et al.
ACS MACRO LETTERS (2017)
A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer
Stefano Coppola et al.
DRUG RESISTANCE UPDATES (2017)
Molecular Events in the Natural History of Pancreatic Cancer
Leslie E. Oldfield et al.
TRENDS IN CANCER (2017)
Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study
Knut J. Labori et al.
ACTA ONCOLOGICA (2016)
Does long-term survival exist in pancreatic adenocarcinoma?
Myrte Zijlstra et al.
ACTA ONCOLOGICA (2016)
Key role of pancreatic stellate cells in pancreatic cancer
Srinivasa P. Pothula et al.
CANCER LETTERS (2016)
TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3
Rachel A. Hesler et al.
CARCINOGENESIS (2016)
Current Standard and Future Perspectives in First and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma
Volker Ellenrieder et al.
DIGESTION (2016)
Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival
Sonja M. Woermann et al.
GASTROENTEROLOGY (2016)
SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts
Harrison Kim et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Key players in pancreatic cancer-stroma interaction: cancer-associated fibroblasts, endothelial and inflammatory cells
Michael Friberg Bruun Nielsen et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Profile of MMP and TIMP Expression in Human Pancreatic Stellate Cells: Regulation by IL-1α and TGFβ and Implications for Migration of Pancreatic Cancer Cells
Vegard Tjomsland et al.
NEOPLASIA (2016)
Pancreatic cancer
Jorg Kleeff et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Synthesis and characterization of TPGS-gemcitabine prodrug micelles for pancreatic cancer therapy
Vaibhav Khare et al.
RSC ADVANCES (2016)
Biocompatible Glycopolymer Nanocapsules via Inverse Miniemulsion Periphery RAFT Polymerization for the Delivery of Gemcitabine
Robert H. Utama et al.
BIOMACROMOLECULES (2015)
T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma
Ingunn M. Stromnes et al.
CANCER CELL (2015)
A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours
B. Venugopal et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Manuel Hidalgo et al.
CLINICAL CANCER RESEARCH (2015)
Enhanced cellular uptake and intracellular drug controlled release of VESylated gemcitabine prodrug nanocapsules
Yanfen Fang et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2015)
Gemcitabine resistance in pancreatic ductal adenocarcinoma
Yoav Binenbaum et al.
DRUG RESISTANCE UPDATES (2015)
Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumourchemoresistance
Camille Duluc et al.
EMBO MOLECULAR MEDICINE (2015)
An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line
Xinzhe Yu et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2015)
Gemcitabine- based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies
Andrei Maksimenko et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2015)
Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice
Yanyun Xu et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2015)
Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer
Christopher Poon et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future
Gaurav Goel et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors
Kentaro Minami et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2015)
The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2
Nicolas Skrypek et al.
ONCOTARGET (2015)
Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells
Masaya Jimbo et al.
ONCOTARGET (2015)
Paracrine SDF-1α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells
Hui Zhang et al.
ONCOTARGET (2015)
Establishment of human pancreatic cancer gemcitabine-resistant cell line with ribonucleotide reductase overexpression
Congfei Wang et al.
ONCOLOGY REPORTS (2015)
Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival
Berna C. Oezdemir et al.
CANCER CELL (2014)
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Andrew D. Rhim et al.
CANCER CELL (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
Stromal reengineering to treat pancreas cancer
Ingunn M. Stromnes et al.
CARCINOGENESIS (2014)
Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy
Mara H. Sherman et al.
CELL (2014)
The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: Enhanced membrane permeability and enzymatic stability
Yasuhiro Tsume et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2014)
Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer
Lucas de Sousa Cavalcante et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Preparation, optimization and in vitro characterization of stearoyl-gemcitabine polymeric micelles: A comparison with its self-assembled nanoparticles
Zahra Daman et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2014)
Transport properties of pancreatic cancer describe gemcitabine delivery and response
Eugene J. Koay et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development
Magdalena Slusarczyk et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
William Greenhalf et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase
N. Weizman et al.
ONCOGENE (2014)
Nab-Paclitaxel for Metastatic Pancreatic Cancer: Clinical Outcomes and Potential Mechanisms of Action
Salah-Eddin Al-Batran et al.
ONCOLOGY RESEARCH AND TREATMENT (2014)
Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer
Eugene J. Koay et al.
PHYSICAL BIOLOGY (2014)
The Dipeptide Monoester Prodrugs of Floxuridine and Gemcitabine-Feasibility of Orally Administrable Nucleoside Analogs
Yasuhiro Tsume et al.
PHARMACEUTICALS (2014)
Self-Assembling, Amphiphilic Polymer-Gemcitabine Conjugate Shows Enhanced Antitumor Efficacy Against Human Pancreatic Adenocarcinoma
Deepak Chitkara et al.
BIOCONJUGATE CHEMISTRY (2013)
The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression
Saijie Zhu et al.
BIOMATERIALS (2013)
Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer
Niranjan Awasthi et al.
CARCINOGENESIS (2013)
A Starring Role for Stellate Cells in the Pancreatic Cancer Microenvironment
Minoti V. Apte et al.
GASTROENTEROLOGY (2013)
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Michael A. Jacobetz et al.
GUT (2013)
Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
Elizabeth Poplin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A Phase 1 Comparative Pharmacokinetic and Cardiac Safety Study of Two Intravenous Formulations of CO-101 in Patients With Advanced Solid Tumors
F. E. Stuurman et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes
Raghu Kadaba et al.
JOURNAL OF PATHOLOGY (2013)
Understanding the stroma of pancreatic cancer: co-evolution of the microenvironment with epithelial carcinogenesis
Mert Erkan
JOURNAL OF PATHOLOGY (2013)
The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29
James D. Young et al.
MOLECULAR ASPECTS OF MEDICINE (2013)
Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications
Elodie Moysan et al.
MOLECULAR PHARMACEUTICS (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family
N. Skrypek et al.
ONCOGENE (2013)
CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer
Albrecht Neesse et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Christine Feig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
Vikash P. Chauhan et al.
NATURE COMMUNICATIONS (2013)
DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells
Yuriko Saiki et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study
Y. Nakai et al.
BRITISH JOURNAL OF CANCER (2012)
Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
Paolo P. Provenzano et al.
CANCER CELL (2012)
Overcoming nucleoside analog chemoresistance of pancreatic cancer: A therapeutic challenge
Sau Wai Hung et al.
CANCER LETTERS (2012)
Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: Molecular basis for therapeutic implications
Xiangyu Kong et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2012)
Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma
Raphael Marechal et al.
GASTROENTEROLOGY (2012)
Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1
Woon-Gye Chung et al.
JOURNAL OF CONTROLLED RELEASE (2012)
The role of stroma in pancreatic cancer: diagnostic and therapeutic implications
Mert Erkan et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2012)
Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices
Vanessa Allain et al.
NUCLEIC ACIDS RESEARCH (2012)
The Mucin MUC4 and Its Membrane Partner ErbB2 Regulate Biological Properties of Human CAPAN-2 Pancreatic Cancer Cells via Different Signalling Pathways
Nicolas Jonckheere et al.
PLOS ONE (2012)
nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer
Kristopher K. Frese et al.
CANCER DISCOVERY (2012)
Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer
Anastasios Dimou et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2012)
CNT1 Expression Influences Proliferation and Chemosensitivity in Drug-Resistant Pancreatic Cancer Cells
Yangzom D. Bhutia et al.
CANCER RESEARCH (2011)
Stromal biology and therapy in pancreatic cancer
Albrecht Neesse et al.
GUT (2011)
In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles
Brian R. Sloat et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2011)
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models
Andries M. Bergman et al.
INVESTIGATIONAL NEW DRUGS (2011)
A phosphoramidate ProTide (NUC-1031) and acquired and intrinsic resistance to gemcitabine
C. McGuigan et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy
Geetanjali Arya et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2011)
Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer
Soukaina Rejiba et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2011)
Integrating pharmacogenetics into gemcitabine dosing-time for a change?
Joseph Ciccolini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Pancreatic cancer: understanding and overcoming chemoresistance
Zhiwei Wang et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects
Hiroshi Maeda
BIOCONJUGATE CHEMISTRY (2010)
Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer
Mallaredy Vandana et al.
BIOMATERIALS (2010)
Systemic Administration of Polymeric Nanoparticle-Encapsulated Curcumin (NanoCurc) Blocks Tumor Growth and Metastases in Preclinical Models of Pancreatic Cancer
Savita Bisht et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Delivering nanomedicine to solid tumors
Rakesh K. Jain et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
Naotake Funamizu et al.
ONCOLOGY REPORTS (2010)
Contribution of Thymidylate Synthase to Gemcitabine Therapy for Advanced Pancreatic Cancer
Shuji Komori et al.
PANCREAS (2010)
pp32 (ANP32A) Expression Inhibits Pancreatic Cancer Cell Growth and Induces Gemcitabine Resistance by Disrupting HuR Binding to mRNAs
Timothy K. Williams et al.
PLoS One (2010)
Combinatorial Drug Conjugation Enables Nanoparticle Dual-Drug Delivery
Santosh Aryal et al.
SMALL (2010)
Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy
Hayato Fujita et al.
NEOPLASIA (2010)
HuR Status is a Powerful Marker for Prognosis and Response to Gemcitabine-Based Chemotherapy for Resected Pancreatic Ductal Adenocarcinoma Patients
Nathan G. Richards et al.
ANNALS OF SURGERY (2010)
Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitro
Jin-ming Li et al.
ACTA PHARMACOLOGICA SINICA (2009)
Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin
S. Bafna et al.
BRITISH JOURNAL OF CANCER (2009)
The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase
Christina L. Costantino et al.
CANCER RESEARCH (2009)
Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma
Raphael Marechal et al.
CLINICAL CANCER RESEARCH (2009)
Clinical pharmacology and pharmacogenetics of gemcitabine
Andrea Wong et al.
DRUG METABOLISM REVIEWS (2009)
Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
James J. Farrell et al.
GASTROENTEROLOGY (2009)
Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions
Roland Andersson et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2009)
Gemcitabine-Based Chemogene Therapy for Pancreatic Cancer Using Ad-dCK::UMK GDEPT and TS/RR siRNA Strategies
Soukaina Regiba et al.
NEOPLASIA (2009)
Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent
Chitta Ranjan Patra et al.
CANCER RESEARCH (2008)
Gemcitabine resistance in pancreatic cancer: Picking the key players
Michael P. Kim et al.
CLINICAL CANCER RESEARCH (2008)
Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules
Barbara Stella et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2007)
Synthesis and biological activity of a gemcitabine phosphoramidate prodrug
Weidong Wu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas
Takao Itoi et al.
JOURNAL OF GASTROENTEROLOGY (2007)
MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins
Pallavi Chaturvedi et al.
MOLECULAR CANCER RESEARCH (2007)
Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer
Shin Nakahira et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
Y. Nakano et al.
BRITISH JOURNAL OF CANCER (2007)
Characterization of lipophilic gemcitabine prodrug - Liposomal membrane interaction by differential scanning calorimetry
Francesco Castelli et al.
MOLECULAR PHARMACEUTICS (2006)
Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: Relationship to molecular mechanisms of gemcitabine resistance and survival
V Sebastiani et al.
CLINICAL CANCER RESEARCH (2006)
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine
E Giovannetti et al.
CANCER RESEARCH (2006)
Targeting multidrug resistance in cancer
G Szakács et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate
P Chen et al.
ANTI-CANCER DRUGS (2006)
cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer
P Sève et al.
LUNG CANCER (2005)
Synthesis and biological evaluation of gemcitabine-lipid conjugate (NE06002)
SM Ali et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Determinants of sensitivity and resistance to gemcitabine: The roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer
H Achiwa et al.
CANCER SCIENCE (2004)
Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs
ML Immordino et al.
JOURNAL OF CONTROLLED RELEASE (2004)
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma
J Spratlin et al.
CLINICAL CANCER RESEARCH (2004)
Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway
AK Fukunaga et al.
PHARMACOGENOMICS JOURNAL (2004)
Human cytosolic 5′-nucleotidase I -: Characterization and role in nucleoside analog resistance
SA Hunsucker et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
